1. A phase 2 trial of the efficacy and safety of evinacumab in patients with severe hypertriglyceridemia. (August 2021) Authors: Rosenson, R.S.; Gaudet, D.; Ballantyne, C.M.; Baum, S.J.; Bergeron, J.; Kershaw, E.E.; Moriarty, P.M.; Rubba, P.; Banerjee, P.; Ponda, M.P.; Pordy, R.; Son, V.; Rader, D.J. Journal: Atherosclerosis Issue: Volume 331(2021) Page Start: e293 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Effects of lipoprotein apheresis on PCSK9 levels. (May 2015) Authors: Julius, U.; Milton, M.; Stoellner, D.; Rader, D.; Gordon, B.; Polk, D.; Waldmann, E.; Parhofer, K.G.; Moriarty, P.M. Journal: Atherosclerosis Issue: Volume 18(2015) Page Start: 180 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Evaluating the effect of lipid-apheresis on evinacumab and angiopoietin-like 3 (ANGPTL3) levels. (December 2020) Authors: Moriarty, P.M.; Dutton, J.-A.; Gorby, L.; Vance, J.; Ali, S.; Zhao, A.; Khilla, N.; Alejandro, M.; Rodriguez, J.; Rajadhyaksha, M.; Andisik, M.; Gipe, D.A.; Zhang, Y. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. First on-line survey of an international multidisciplinary working group (MightyMedic) on current practice in diagnosis, therapy and follow-up of dyslipidemias. (May 2015) Authors: Stefanutti, C.; D'Alessandri, G.; Petta, A.; Harada-Shiba, M.; Julius, U.; Soran, H.; Moriarty, P.M.; Romeo, S.; Drogari, E.; Jaeger, B.R. Journal: Atherosclerosis Issue: Volume 18(2015) Page Start: 241 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Impact of lipoprotein apheresis on serum myeloperoxidase levels in patients with familial hypercholesterolemia. Issue 1 (July 2015) Authors: Sehar, N.; Moriarty, P.M. Journal: Atherosclerosis Issue: Volume 241:Issue 1(2015) Page Start: e200 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Impact of lipoprotein apheresis on serum myeloperoxidase levels in patients with familial hypercholesterolemia. Issue 1 (July 2015) Authors: Sehar, N.; Moriarty, P.M. Journal: Atherosclerosis Issue: Volume 241:Issue 1(2015) Page Start: e200 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. LDL-cholesterol corrected for LP(A)-cholesterol, risk thresholds and cardiovascular events. (December 2020) Authors: Willeit, P.; Yeang, C.; Moriarty, P.M.; Tschiderer, L.; Varvel, S.A.; Mcconnell, J.P.; Tsimikas, S. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e34 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Rationale and design of a clinical trial to assess Lp(a) lowering with ionis-apo(a)-LRX in patients undergoing apheresis for elevated Lp(a) and recurrent cardiovascular events. (September 2016) Authors: Moriarty, P.M.; Thiessen, E.S.; Witztum, J.L.; Viney, N.J.; Tsimikas, S. Journal: Atherosclerosis Issue: Volume 252(2016) Page Start: e123 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗